abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

이 페이지는 한국어로 제공되지 않으며 English로 표시됩니다.

기사

2010년 6월 20일

저자:
Access to Medicine Index

European drug companies lead 'Access to Medicine Index'

…The Access to Medicine Index ranks 20 of the world's largest pharmaceutical companies on their efforts to make sure that medicines are made for, and reach, people in developing countries…The Access to Medicine Index 2010 identifies GlaxoSmithKline as current industry leader in improving access...Following in its footsteps are Merck, Novartis, Gilead Sciences, and Sanofi-Aventis...Pfizer moved up strongly in the ranking; Bayer, Bristol-Myers Squibb, Merck KGaA and Novo Nordisk [part of the Novo Group] were down…Also, generic drug makers, who do less research but produce low-cost off-patent drugs, now have a separate ranking. Ranbaxy Laboratories and Cipla top that list…